Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124

PHASE2CompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

April 6, 2022

Primary Completion Date

November 7, 2023

Study Completion Date

November 7, 2023

Conditions
Hypertension
Interventions
DRUG

CIN-107

2 mg of CIN-107, once a day for 52 weeks

Trial Locations (36)

11235

Research Site, Brooklyn

20110

Research Site, Manassas

33012

Research Site, Hialeah

33024

Research Site, Hollywood

33027

Research Site, Pembroke Pines

33165

Research Site, Miami

33166

Research Site, Doral

33173

Research Site, Miami

33467

Research Site, Lake Worth

33765

Research Site, Clearwater

33880

Research Site, Winter Haven

36571

Research Site, Saraland

38654

Research Site, Olive Branch

43213

Research Site, Columbus

46112

Research Site, Brownsburg

48085

Research Site, Troy

60101

Research Site, Addison

60607

Research Site, Chicago

61550

Research Site, Morton

70124

Research Site, New Orleans

73013

Research Site, Edmond

75006

Research Site, Carrollton

75234

Research Site, Dallas

76550

Research Site, Lampasas

77040

Research Site, Houston

78209

Research Site, San Antonio

78628

Research Site, Georgetown

78705

Research Site, Austin

84120

Research Site, West Valley City

90057

Research Site, Los Angeles

90255

Research Site, Huntington Park

91324

Research Site, Northridge

91402

Research Site, Panorama City

91405

Research Site, Van Nuys

92056

Research Site, Oceanside

95648

Research Site, Lincoln

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY